First Eagle Investment Management, LLC – ‘SC 13G/A’ on 2/5/16 re: First Eagle Investment Management, LLC

On:  Friday, 2/5/16, at 5:35pm ET   ·   As of:  2/4/16   ·   Accession #:  1325447-16-63   ·   File #:  5-89314

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Amendment to Statement of Beneficial Ownership   —   Schedule 13G
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: SC 13G/A    Amendment to Statement of Beneficial Ownership         4     13K 

Document Table of Contents

SC 13G/A
1st Page of 4
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
UNITED STATES SECURITIES AND                                                    
EXCHANGE COMMISSION                                                             
Washington, D.C.  20549                                                         

Schedule 13G/A                                                                  

Under the Securities Exchange Act of 1934                                       
(Amendment No. 1)*                                                              
(RULE 13d-102)                                                                  

Information to be included in statements filed                                  
pursuant to Rule 13d-1 (b) (c) and (d) and Amendments thereto                   
filed pursuant to Rule 13d-2 (b).                                               

KaloBios Pharmaceuticals, Inc.                                                  
(Name of Issuer)                                                                

Common shares                                                                   
(Title of Class of Securities)                                                  

48344T100                                                                       
(CUSIP/SEDOL Number)                                                            

December 31, 2015                                                               
(Date of Event which Requires Filing of this Statement)                         

Check the appropriate box to designate the rule pursuant                        
to which this Schedule is filed:                                                

[X]     Rule 13d-1 (b)                                                          
[ ]     Rule 13d-1 (c)                                                          
[ ]     Rule 13d-1 (d)                                                          

*The remainder of this cover page shall be filled out for a     
reporting person's initial filing on this form with respect to the              
subject class of securities, and for any subsequent amendment                   
containing information which would alter the disclosures provided               
in a prior cover page.                                                          

  The information required in the remainder of this cover page shall
not be deemed to be "filed" for the purpose of Section 18 of the Securities     
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of         
that section of the Act but shall be subject to all other provisions of         
the Act (however, see the Notes).                                               

SC 13G/A
2nd Page of 4
TOC
1st
Previous
Next
↓Bottom
Just 2nd
SCHEDULE 13G/A                                                                  

Issuer: KaloBios Pharmaceuticals, Inc.  CUSIP No.: 48344T100                    

1       NAMES OF REPORTING PERSONS I.R.S.                                       
IDENTIFICATION NOS. OF ABOVE PERSONS                            

First Eagle Investment Management, LLC                          
Tax ID # 57-1156902                                             

2       CHECK THE APPROPRIATE BOX IF A MEMBER                                   
OF A GROUP                                                      
(a)                                                             
(b)                                                             

3       SEC USE ONLY                                                            

4       CITIZENSHIP OR PLACE OF ORGANIZATION                                    

State of Delaware                                               

NUMBER OF SHARES        5  SOLE VOTING POWER - 0                                
BENEFICIALLY            6  SHARED VOTING POWER -  0                             
OWNED BY EACH           7  SOLE DISPOSITIVE POWER - 0                           
REPORTING PERSON        8  SHARED DISPOSITIVE POWER - 0                         
WITH:                                                                           

9       AGGREGATE AMOUNT BENEFICIALLY OWNED                                     
BY EACH REPORTING PERSON                                        

0                                                               

10      CHECK IF THE AGGREGATE AMOUNT IN                                        
ROW (11) EXCLUDES CERTAIN SHARES                                

N/A                                                             

11      PERCENT OF CLASS REPRESENTED BY AMOUNT                                  
IN ROW 9:                                                       

0.00%                                                           

12      TYPE OF REPORTING PERSON                                                

IA                                                              

SC 13G/A
3rd Page of 4
TOC
1st
Previous
Next
↓Bottom
Just 3rd
SCHEDULE 13G/A                                                                  

Issuer: KaloBios Pharmaceuticals, Inc.  CUSIP No.: 48344T100                    

ITEM 1                                                                          

(a)     Name of Issuer: KaloBios Pharmaceuticals, Inc.                          

(b)     Address of Issuer's Principal Executive Offices:                        

442 Littlefield Avenue                                          
South San Francisco, CA 94080                                   

ITEM 2                                                                          

(a)     Name of Person Filing: First Eagle Investment Management, LLC           

(b)     Address of Principal Business Office:                                   

1345 Avenue of the Americas                                     
New York, NY 10105                                              

(c)     Citizenship: Delaware, USA                                              

(d)     Title of Class of Securities:                                           

Common Stock                                                    

(e)     CUSIP No.: 48344T100                                                    

ITEM 3                                                                          

If this statement is filed pursuant to Sections 240.                            
13d-1(b), or 240.13d-2(b) or (c), check whether                                 
the person filing is a:                                                         

(a)     [  ]    Broker or dealer registered under                               
Section 15 of the Act (15 U.S.C. 78o);          

(b)     [  ]    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);  

(c)     [  ]    Insurance Company as defined in section                         
3(a)(19) of the Act (15 U.S.C. 78C);            

(d)     [  ]    Investment company registered under Section                     
8 of the Investment Company Act if 1940         
(15 U.S.C. 80a-8);                              

(e)     [X]     An investment adviser in accordance with Section                
240.13d-1(b)(1)(ii)(E);                         

(f)     [  ]    An employee benefit plan or endowment fund in accordance with   
Section 240.13d-1(b)(1)(ii)(F);                 

(g)     [  ]    A parent holding company or control person in accordance with   
Section 240.13d-1(b)(1)(ii)(G);                 

(h)     [  ]    A savings associations as defined in Section 3(b) of the        
Federal Deposit Insurance Act (12 U.S.C. 1813); 

(i)     [  ]    A church plan that is excluded from the                         
             definition of an insurance company under Section 3 (c)(14) of
     the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)     [  ]    Group, in accordance with section 240.13d-1 (b)(1)(ii)(J).      

SC 13G/A
Last Page of 4
TOC
1st
Previous
Next
↓Bottom
Just 4th
SCHEDULE 13G/A                                                                  

Issuer: KaloBios Pharmaceuticals, Inc.  CUSIP No.: 48344T100                    

ITEM 4. Ownership.                                                              

ITEM 5. Ownership of Five Percent or Less of a Class.                           

       If this statement is being filed to report the fact that as of the date
       hereof the reporting person has ceased to be the beneficial owner of more
      than five percent of the class of securities, check the following: [x]

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON         

N/A                                                             

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE  
   SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL
PERSON.                                                         

N/A                                                             

ITEM 8. Identification and Classification of Members of the Group.              

N/A                                                             

ITEM 9. Notice of Dissolution of Group                                          

N/A                                                             

ITEM 10. Certification                                                          

By signing below I certify that, to the best of my knowledge and
      belief, the securities referred to above were acquired and held in the
      ordinary course of business and were not acquired and are not held for the
     purpose of or with the effect of changing or influencing the control of the
   issuer of such securities and were not acquired and are not held in
      connection with or as a participant in any transaction having that purpose
of effect.                                                      

SIGNATURE                                                                       

After reasonable inquiry and to the best of my knowledge and belief,            
I certify that the information set forth in this statement is true,             
complete and correct.                                                           

Date:           February 4, 2016                                                

Signature:      /s/ Michael M. Kellen                                           

Name/Title:     Michael M. Kellen, Director                                     

</PAGE>                                                                         

Dates Referenced Herein   and   Documents Incorporated by Reference

				Referenced-On Page
This ‘SC 13G/A’ Filing		Date		First		Last			Other Filings
Filed on:		2/5/16							SC 13G,  SC 13G/A
Filed as of:		2/4/16		4					SC 13G,  SC 13G/A
		12/31/15		1
									List all Filings